Skip to main content Back to Top
Advertisement

12/19/2016

Haemophilus B Conjugate Vaccine

Reason for the Shortage

    • GlaxoSmithKline relaunched Hiberix in August 2016.[1]
    • Sanofi Pasteur had ActHIB in short supply due to the shortage of other combination vaccines (eg, Pentacel).[2,3]
    • Merck has Pedvax HIB (Haemophilus b meningococcal protein conjugate vaccine) available.[4]

Available Products

    • ActHIB intramuscular powder for solution, Sanofi Pasteur, 10 mcg, single dose vial, 5 count, NDC 49281-0545-05
    • Hiberix intramuscular powder for solution, GlaxoSmithKline, 10 mcg, single dose vial, 10 count, NDC 58160-0818-11
    • PedvaxHIB intramuscular solution for injection, Merck, 7.5 mcg, 0.5 mL single dose vial, 10 count, NDC 00006-4897-00

Estimated Resupply Dates

    • All presentations are currently available.

Implications for Patient Care

    • ActHIB is labeled for primary and booster immunization against infection with H. influenzae type B as a 4-dose series in pediatric patients ages 2 months to 5 years.[5]
    • Hiberix is labeled for primary and booster immunization against infection with H. influenzae type B in patients ages 6 weeks to 4 years of age.[6]
    • PedvaxHIB is labeled for primary and booster immunization against infection with H. influenzae type B in patients 2 to 71 months of age.[7]

Safety

    • Ensure patients receive the adequate number of vaccinations as outlined by the Centers for Disease Control and Prevention (CDC) Recommended Immunization Schedules.[8,9]

Alternative Agents & Management

    • The CDC has a guidance document available for clinicians during this shortage. Available at: https://www.cdc.gov/vaccines/hcp/clinical-resources/downloads/pentacel-delay.pdf.[10]

References

    1. GlaxoSmithKline (personal communications). January 14, February 3, March 7, April 26, June 7, July 22, August 1, September 6, November 16, and December 13, 2016.
    2. Sanofi Pasteur (personal communications). January 14, February 3, March 7, April 26, May 26, July 20, August 24, September 6, November 16, and December 12, 2016.
    3. Sanofi Pasteur. Dear Health Care Provider Letter (December 2015). Available at: https://www.vaccineshoppe.com/mailing/VSH/2015/12allo30341/index.html. Accessed January 14, 2016.
    4. Merck (personal communications and website). January 25, March 7, April 26, May 26, July 22, August 3, September 6, November 17, and December 12, 2016.
    5. Sanofi Pasteur. ActHIB Haemophilus b Conjugate Vaccine (Tetanus toxoid conjugate) Solution for Intramuscular Injection [product labeling]. Swiftwater, PA: Sanofi Pasteur; 2015.
    6. GlaxoSmithKline. Hiberix Haemophilus b Conjugate Vaccine (Tetanus toxoid conjugate) Solution for Intramuscular Injection [product labeling]. Research Triangle Park, NC: GlaxoSmithKline, January 2016.
    7. Merck & Company. Liquid PedvaxHIB Haemophilus b Conjugate Vaccine (Meningococcal protein conjugate) Injection [product labeling]. Whitehouse Station, NJ: Merck & Company; December 2010.
    8. Centers for Disease Control and Prevention (CDC). General Recommendations on Immunization, Recommendations of the Advisory Committee on Immunization Practice. MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(RR02):1-60. Available online at: http://www.cdc.gov/mmwr/pdf/rr/rr6002.pdf. Accessed January 14, 2016.
    9. Department of Health and Human Services, Centers for Disease Control and Prevention. Recommended Immunization Schedule for Persons Ages 0 to 18 Years, United States 2015. Available at: http://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Accessed January 14, 2016.
    10. Department of Health and Human Services, Centers for Disease Control and Prevention. Guidance for vaccinating children during the 2015-16 Pentacel manufacturing delay. Available at http://www.cdc.gov/vaccines/vac-gen/shortages/downloads/pentacel-delay.pdf. Accessed January 14, 2016.

Updated

Updated December 19, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 14, 2016 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT